department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

RIVAROXABAN · pharmadog

pharmadog
drugs
RIVAROXABAN

drug

patient view →

RIVAROXABAN

Marketedupdated 2mo ago

by Reddy US Therapeutics Inc

Approved

annual revenue · 2024–2024peak $2.1B

community read0 votes

indications

investigational

Atrial Fibrillation

all catalysts(4)

approval · 4

News(0)

no news has mentioned this drug yet

brand

RIVAROXABAN

generic

RIVAROXABAN

indication

Atrial Fibrillation

phase

marketed

approved

2011-07-01

RIVAROXABAN — FDA approval

RIVAROXABAN — FDA approval

RIVAROXABAN — FDA approval

RIVAROXABAN — FDA approval

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 17, 2034

~7.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Aug 17, 2034patentUS 9539218*PED
Aug 17, 2034patentUS 9539218*PED
Aug 17, 2034patentUS 9539218*PED
Feb 17, 2034method-of-use (U-3289)US 9539218
Feb 17, 2034method-of-use (U-3285)US 9539218
Feb 17, 2034method-of-use (U-3288)US 9539218

Data sources

openFDA · ClinicalTrials.gov

last refreshed just now

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

tagApproval92 co-mentions · 46 sources
drugXarelto85 co-mentions · 46 sources
tagSmall Molecule46 co-mentions · 46 sources
companyLupin Ltd1 co-mentions · 1 sources

Trials studying RIVAROXABAN

N/ADEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosisrecruitingn=300
phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosisactive not recruitingn=1,683
—A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)not yet recruitingn=850
—An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolismcompletedn=320
N/APill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablationrecruitingn=400
phase1A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participantsrecruitingn=186
—An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedureactive not recruitingn=61
phase3Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Diseasecompletedn=1,753

more trials →